Keros Therapeutics, Inc. (KROS)
$10.03
+0.22 (+2.18%)Delayed quote.
Price history
Daily close- Start
- $17.37
- Latest close
- $10.03
- Period change
- -42.26%
- Period low
- $9.17
- Period high
- $21.84
Key metrics
- Market cap
- $202.13M
- Volume
- 167.0K
- Average volume
- 191.1K
- 52-week range
- $8.98 – $22.55
- Beta
- 1.02
- Last dividend
- —
- EPS (TTM)
- -$2.81
- P/E ratio
- 8.70
- Revenue (TTM)
- $40.76M
- Net income (TTM)
- -$61.73M
- Total assets
- $307.37M
- Total debt
- $15.11M
- Cash and equivalents
- $259.46M
Key financials (trailing twelve months).
Company profile
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Jasbir S. Seehra
- Employees
- 87
- Headquarters
- Lexington, MA, US
- IPO date
- 2020-04-08
- Website
- https://www.kerostx.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $244.06M | $3.55M | $151.0K |
| Gross profit | $242.55M | $3.55M | $151.0K |
| Operating income | $70.62M | -$210.83M | -$169.94M |
| EBITDA | $93.41M | -$185.82M | -$152.18M |
| Net income | $87.01M | -$187.35M | -$152.99M |
| Diluted EPS | $2.30 | -$5.00 | -$5.20 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $287.42M | $559.93M | $331.15M |
| Total assets | $338.02M | $615.89M | $370.02M |
| Total liabilities | $34.89M | $44.33M | $37.81M |
| Total debt | $16.88M | $18.86M | $14.44M |
| Shareholders’ equity | $303.13M | $571.55M | $332.21M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $107.50M | -$160.87M | -$124.51M |
| Capital expenditure | -$1.55M | -$1.93M | -$2.46M |
| Free cash flow | $105.95M | -$162.80M | -$126.97M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $40.01M | $0 | $367.0K | $385.0K | $14.26M | $18.17M |
| Gross profit | $40.01M | $0 | -$36.0K | -$15.0K | $13.87M | $17.80M |
| Operating income | $12.82M | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M |
| EBITDA | $14.93M | -$28.31M | -$23.30M | -$24.57M | -$8.31M | -$32.55M |
| Net income | $14.15M | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M |
| Diluted EPS | $0.70 | -$1.45 | -$1.21 | -$0.86 | -$0.18 | -$0.76 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $259.46M | $257.61M | $281.50M | $287.42M | $693.47M | $690.22M |
| Total assets | $307.37M | $287.60M | $312.29M | $338.02M | $742.78M | $757.16M |
| Total liabilities | $28.27M | $25.28M | $26.66M | $34.89M | $39.20M | $50.43M |
| Total debt | $15.11M | $15.72M | $16.31M | $16.88M | $17.43M | $17.95M |
| Shareholders’ equity | $279.10M | $262.32M | $285.63M | $303.13M | $703.58M | $706.73M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $3.39M | -$20.42M | -$3.53M | -$27.29M | $3.25M | -$29.62M |
| Capital expenditure | -$59.0K | -$155.0K | -$73.0K | -$134.0K | -$132.0K | -$720.0K |
| Free cash flow | $3.33M | -$20.58M | -$3.60M | -$27.43M | $3.12M | -$30.34M |